MedTrace Logo

Prevalence of Sarcopenia and Its Geriatric Features

NCT02664376 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 834

Last updated 2018-01-26

No results posted yet for this study

Summary

The goal of this study is to determine the prevalence of sarcopenia in a geriatric hospital ward.

Sarcopenia is defined by a loss of muscle mass, loss of muscle strength and loss of muscle quality. It is a geriatric syndrome that, to this date, is not systematically tracked in clinical practice.

In order to detect sarcopenia, the investigators will use the operational definition proposed by the European Working Group (EWGSOP) involving the measure of three parameters, namely the speed of walking, the muscle strength and the measurement of the muscular mass.

Conditions

Interventions

OTHER

Sarcopenia detection

The assessment of sarcopenia is performed according to the recommendations of the EWGSOP (European Working Group on Sarcopenia in Older people). Three measurements are made: * Muscle mass measurement by dual energy X-ray absorptiometry (DEXA). * Walking speed measurement * Hand grip test A diagnosis of sarcopenia is established if the walking speed is inferior to 0.8 m/sec, the muscular strength is low and the muscular mass is low. Data regarding the geriatric characteristics of this sarcopenic population will be collected.

Sponsors & Collaborators

  • Brugmann University Hospital

    lead OTHER

Principal Investigators

  • Robin Barré, MD · CHU Brugmann

  • Murielle Surquin, MD · CHU Brugmann

  • Florence Benoît, MD · CHU Brugmann

  • Marie Claessens, MD · CHU Brugmann

Eligibility

Min Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-01-01
Primary Completion
2018-01-18
Completion
2018-01-18

Countries

  • Belgium

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02664376 on ClinicalTrials.gov